Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2023-184406

Published: 2023

Journal Articles

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Matthew J. Frigault, Richard T Maziarz, Jae H. Park, Aleksandr Lazaryan, Nirav N. Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L Phillips, Lea M Burke, Jing Lei, Rodica Morariu-Zamfir, John F. DiPersio

Blood (2023) 142 (Supplement 1): 356.

https://doi.org/10.1182/blood-2023-180205

Published: 2023

Journal Articles

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Blood (2023) 142 (Supplement 1): 3512.

https://doi.org/10.1182/blood-2023-185097

Published: 2023

Journal Articles

Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2023-187294

Published: 2023

Journal Articles

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2023-185117

Published: 2023

Journal Articles

Clinical Outcomes of Adults Undergoing Allogeneic Stem Cell Transplant for Secondary Acute Lymphoblastic Leukemia

Vivian Irizarry Gatell, Denise Kalos, Joseph A. Pidala, Hany Elmariah, Farhad Khimani, Asmita Mishra, Taiga Nishihori, Michael D. Jain, Michael Neider, Lia Perez, Sayeef Mirza, Bijal D. Shah, Leidy Lismeris Isenalumhe, Nelli Bejanyan, Aleksandr Lazaryan, Rawan Faramand

Blood (2023) 142 (Supplement 1): 2830.

https://doi.org/10.1182/blood-2023-180321

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Teresa Caprice, Wenyi Fan, Jongphil Kim, Rawan Faramand, Asmita Mishra, Lia Perez, Farhad Khimani, Aleksandr Lazaryan, Jose L. Ochoa-Bayona, Hien Liu, Michael D. Jain, Michael Nieder, Claudio Anasetti, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan, Hany Elmariah

Blood (2023) 142 (Supplement 1): 390.

https://doi.org/10.1182/blood-2023-186738

Published: 2023

Journal Articles

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Hany Elmariah, Jongphil Kim, Asmita Mishra, Rawan Faramand, Lia Perez, Aleksandr Lazaryan, Farhad Khimani, Hien Liu, Jose L. Ochoa-Bayona, Michael Nieder, Nicholas Figura, Timothy J Robinson, Taiga Nishihori, Claudio Anasetti, Joseph A. Pidala, Nelli Bejanyan

Blood (2023) 142 (Supplement 1): 4900.

https://doi.org/10.1182/blood-2023-187473

Published: 2023

Journal Articles

Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4884.

https://doi.org/10.1182/blood-2023-187078

Published: 2023

Journal Articles

Interim Results of a Prospective Trial Testing Vaccination Against Pneumococcus before and after CD19 CAR T Cell Therapy to Optimize Humoral Immunity

Dasom Lee, Abida Poovathukaran Babu, Salvatore A. Corallo, Meghan A. Menges, Melanie J. Hidalgo-Vargas, Danielle M. Ames, Aleksandr Lazaryan, Taiga Nishihori, Farhad Khimani, Sameh Gaballa, Bijal D. Shah, Javier Pinilla Ibarz, Julio C. Chavez, Michael D. Jain, Frederick L. Locke

Blood (2022) 140 (Supplement 1): 4595–4597.

https://doi.org/10.1182/blood-2022-165776

Published: 2022

Journal Articles

Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-Versus-Host Disease

Eric Gaskill, Maya Padilla, Rawan Faramand, Aleksandr Lazaryan, Farhad Khimani, Lia Perez, Joseph Pidala, Rebecca Gonzalez

Blood (2022) 140 (Supplement 1): 10512–10513.

https://doi.org/10.1182/blood-2022-167718

Published: 2022

Journal Articles

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Blood (2022) 140 (Supplement 1): 4678–4680.

https://doi.org/10.1182/blood-2022-171084

Published: 2022

Journal Articles

Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS

Hassaan Yasin, Mahrukh Naqvi, Jongphil Kim, Rawan Faramand, Omar Alexis Castaneda Puglianini, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Michael Nieder, Joseph Pidala, Nelli Bejanyan

Blood (2022) 140 (Supplement 1): 4886–4888.

https://doi.org/10.1182/blood-2022-170696

Published: 2022

Journal Articles

Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Ashley Rose, Jennifer Eatrides, Hayder Saeed, Bijal D. Shah, Aleksandr Lazaryan, Farhad Khimani, Javier Pinilla Ibarz, Hien D. Liu, Frederick L. Locke, Michael D. Jain, Mohamed A. Kharfan-Dabaja, Jongphil Kim, Ling Zhang, Ernesto Ayala, Taiga Nishihori, Lubomir Sokol

Blood (2022) 140 (Supplement 1): 6569–6570.

https://doi.org/10.1182/blood-2022-168347

Published: 2022

Journal Articles

Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Blood (2022) 140 (Supplement 1): 7638–7640.

https://doi.org/10.1182/blood-2022-168400

Published: 2022

Journal Articles

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Blood (2022) 140 (Supplement 1): 10488–10490.

https://doi.org/10.1182/blood-2022-170337

Published: 2022

Journal Articles

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Jennifer Eatrides, Ashley Rose, Ling Zhang, Farhad Khimani, Aleksandr Lazaryan, Bijal D. Shah, Hayder Saeed, Michael D. Jain, Hien D. Liu, Frederick L. Locke, Javier Pinilla Ibarz, Jongphil Kim, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Lubomir Sokol, Taiga Nishihori

Blood (2022) 140 (Supplement 1): 10634–10636.

https://doi.org/10.1182/blood-2022-169200

Published: 2022

Journal Articles

Real-World Patient-Reported Outcomes Among Recipients of Axicabtagene Ciloleucel for Relapsed/Refractory Large B Cell Lymphoma

Heather S.L. Jim, Aasha I. Hoogland, Jennifer M. Logue, Briana Aguilar, Xiaoyin Li, Julia Thornton Snider, Sally West Wade, Christine T Fu, Julio C. Chavez, Michael D. Jain, Aleksandr Lazaryan, Bijal D. Shah, Frederick L. Locke

Blood (2022) 140 (Supplement 1): 5190–5191.

https://doi.org/10.1182/blood-2022-162337

Published: 2022

Journal Articles

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Olalekan O. Oluwole, Saad S. Kenderian, Parveen Shiraz, Reem Karmali, Ran Reshef, Philip L. McCarthy, Nilanjan Ghosh, Aleksandr Lazaryan, Simone Filosto, Soumya Poddar, Daqin Mao, Andrew Peng, Adrian Kilcoyne, Myrna Nahas, Sattva S. Neelapu

Blood (2022) 140 (Supplement 1): 10318–10320.

https://doi.org/10.1182/blood-2022-167688

Published: 2022

Journal Articles

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia

Omar Albanyan, Syeda Mahrukh Hussnain Naqvi, Qianxing Mo, Athena Belfon, Eric Gaskill, Taiga Nishihori, Rawan Faramand, Aleksandr Lazaryan, Doris K. Hansen, Farhad Khimani, Asmita Mishra, Michael Nieder, Lia Perez, Hien D. Liu, Joseph Pidala, Claudio Anasetti, Frederick L. Locke, Nelli Bejanyan, Hany Elmariah

Blood (2022) 140 (Supplement 1): 7664–7666.

https://doi.org/10.1182/blood-2022-166008

Published: 2022

NARROW

A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Clinical Outcomes of Adults Undergoing Allogeneic Stem Cell Transplant for Secondary Acute Lymphoblastic Leukemia

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

Interim Results of a Prospective Trial Testing Vaccination Against Pneumococcus before and after CD19 CAR T Cell Therapy to Optimize Humoral Immunity

Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-Versus-Host Disease

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS

Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Real-World Patient-Reported Outcomes Among Recipients of Axicabtagene Ciloleucel for Relapsed/Refractory Large B Cell Lymphoma

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only